**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**FORM      10-KSB/A**

| x      | ANNUAL                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934                  |
|--------|-------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                          |
|   | For                the fiscal year ended December 31, 2007                                                                    |
|   |                                                                                                                          |
|   | OR                                                                                                                            |
|   |                                                                                                                          |
| o      | TRANSITION                REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF                1934              |
|   |                                                                                                                          |
|   | For                the transition period from ______________________________ to                ______________________________ |

**PROTEIN      POLYMER TECHNOLOGIES, INC.**

| Delaware                                                                                    | 33-0311631                                          |
|---------------------------------------------------------------------------------------------|-----------------------------------------------------|
| (State                or other jurisdiction ofincorporation                or organization) | (I.R.S.                Employer Identification No.) |

----

----

**PROTEIN      POLYMER TECHNOLOGIES, INC.**

**FORM      10-KSB/A**

**AMENDMENT      NO. 1**

**FOR      THE FISCAL YEAR ENDED DECEMBER 31, 2007**

**TABLE      OF CONTENTS**

|                        | **Page**                |
|-----------------------------|-------------------------|
|                        |                    |
| **PART                III** |                    |
|                        | Item                9.  | Directors,                Executive Officers, Promoters and Control Persons; Compliance With                Section                16(a) of the Exchange Act | 2 |
|                        | Item                10. | Executive                Compensation | 4 |
|                        | Item                11. | Security                Ownership of Certain Beneficial Owners and Management and Related                Stockholder Matters | 7 |
|                        | Item                12. | Certain                Relationships and Related Transactions | 10 |
|                        | Item                13. | Exhibits | 11 |
|                        | Item                14. | Principal                Accountant Fees and Services | 11 |
|                        | Signatures              | 12 |

----

**Forward      Looking Statements**

| **Item                9.** | **Directors,                Executive Officers, Promoters and Control Persons; Compliance With                Section                16(a) of the Exchange Act** |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **Name**                                           |   | **Age** |   | **Position                with the Company**                                                                                                   |
|----------------------------------------------------|--------|---------|--------|------------------------------------------------------------------------------------------------------------------------------------------------|
| James                B. McCarthy, M.B.A., J.D. (2) |   | 56      |   | Director,                Interim Chief Executive Officer, Interim President, and Interim Principal                Accounting Officer           |
| Allan                Farber (1)(2)                 |   | 61      |   | Director                                                                                                                                       |
| Kerry                L. Kuhn, M.D. (1)             |   | 58      |   | Director                                                                                                                                       |
| Richard                Adelson (1)(2)              |   | 51      |   | Director                                                                                                                                       |
| William                N. Plamondon III            |   | 60      |   | Director                                                                                                                                       |
| Joseph                Cappello, Ph.D.              |   | 51      |   | Vice                President, Research and Development, Chief Technical Officer and                Director,                Clinical Research |
| Franco                A. Ferrari, Ph.D.            |   | 56      |   | Vice                President, Laboratory Operations and Polymer Production and Director,                Molecular Genetics                    |

----

*James      B. McCarthy*

----

*Allan      Farber*

*Kerry      L. Kuhn, M.D.*

*Richard      Adelson*

*William      N. Plamondon III*

*Joseph      Cappello, Ph.D.,*

*Franco      Ferrari, Ph.D.,*

----

**Section      16(a) Beneficial Ownership Reporting Compliance**

**Code      of Ethics**

| **Item                10.** | **Executive                Compensation** |
|-----------------------------|-------------------------------------------|

**Compensation      of Non-Employee Directors **

**Employment      Agreements**

----

**Summary      Compensation Table – 2007**

| **Name and Principal****Position**                                                                                                                                 |   | **Salary** |    | **Bonus** |   | **Stock****Award** |   | **Option****Award** |   | **Non-Equity****Incentive Plan** **Compensation** |   | **Change in****Pension Value****and****Nonqualified****Deferred****Compensation****Earnings** |   | **All Other****Compensation** |   | **Total** |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|------------|---------|-----------|--------|--------------------|--------|---------------------|--------|-------------------------------------------------------------|--------|---------------------------------------------------------------------------------------------------------|--------|------------------------------------|--------|-----------|--------|
| William N. Plamondon III, Chief                Executive Officer, President, and Principal Accounting Officer, resigned                November 29, 2007 |   | $          | -       |      | $      | -                  |   | $                   | -      |                                                        | $      | -                                                                                                       |   | $                                  | -      |      | $      | - |   | $ | 225,000 | (1)  | $ | 225,000 |   |
|                                                                                                                                                                         |   |       |    |      |   |               |   |                |   |                                                        |   |                                                                                                    |   |                               |   |      |   |   |   |   |   |   |   |   |   |
| James                B. McCarthy, Interim Chief Executive Officer/President/Interim Principal                Accounting Officer, effective November 29, 2007                 |   |       | -       |      |   | -                  |   |                | -      |                                                        |   | -                                                                                                       |   |                               | -      |      |   | - |   |   | 45,000 | (2)   |   | 45,000 |   |
|                                                                                                                                                                         |   |       |    |      |   |               |   |                |   |                                                        |   |                                                                                                    |   |                               |   |      |   |   |   |   |   |   |   |   |   |
| Joseph                Cappello, Ph.D, VP, Research and Development, Chief Technical Officer                and                Director, Clinical Research                    |   |       | 167,860 |      |   | -                  |   |                | -      |                                                        |   | -                                                                                                       |   |                               | -      |      |   | - |   |   | - |   |   | 167,860 |   |
|                                                                                                                                                                         |   |       |    |      |   |               |   |                |   |                                                        |   |                                                                                                    |   |                               |   |      |   |   |   |   |   |   |   |   |   |
| Franco                A. Ferrari, Ph.D, VP, Laboratory Operations and Polymer Production                and                Director, Molecular Genetics                      |   |       | 154,780 |      |   | -                  |   |                | -      |                                                        |   | -                                                                                                       |   |                               | -      |      |   | - |   |   | - |   |   | 154,780 |   |
|                                                                                                                                                                         |   |       |    |      |   |               |   |                |   |                                                        |   |                                                                                                    |   |                               |   |      |   |   |   |   |   |   |   |   |   |
| Erin                Davis, Corporate Secretary, resigned November 29, 2007                                                                                                   |   |       | -       |      |   | -                  |   |                | -      |                                                        |   | -                                                                                                       |   |                               | -      |      |   | - |   |   | - |   |   | - |   |

| (1)    | Mr.                Plamondon’s compensation for the year ended December 31, 2007 consisted of                consulting fees payable to R. I. Heller & Co., LLC, of which he is the                chief executive officer. The monthly fee is $25,000 of which $50,000                was                paid in cash during 2007 and $175,000 will be paid in the future.              |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                                                                                                                                                                               |
| (2)    | Mr.                McCarthy’s compensation for the year ended December 31, 2007 consisted of                consulting fees payable to Gemini Consulting Group, Inc., of which                he is                the chief executive officer. The monthly fee is $15,000 of which                $30,000                was paid in cash during 2007 and $15,000 was paid in January 2008. |

----

**Outstanding      Equity Awards at Year End - 2007**

|                                     |   | **Option/Warrants                Awards**                                                        |      | **Stock                Awards**                                                                    |   |
|------------------------------------------|--------|--------------------------------------------------------------------------------------------------|-----------|----------------------------------------------------------------------------------------------------|--------|
| **Name**                                 |   | **Number of****Securities****Underlying****Unexercised****Options (#)****Exercisable** |      | **Number of****Securities****Underlying****Unexercised****Options (#)****Unexercisable** |   | **Equity****Incentive****Plan****Awards****Number of****Securities****Underlying****Unexercised****Unearned****Options (#)** |   | **Option****Exercise****Price** |   | **Option****Expiration****Date** |   | **Number****of****Shares****or Units****of Stock****That****Have****Not****Vested****(#)** |   | **Market****Value****of****Shares****or Unit****That****Have****Not****Vested** |   | **Equity****Incentive****Plan****Awards:****Number****of****Unearned****Shares,****Units or****Other****Rights****That****Have Not****Vested****(#)** |   | **Equity****Incentive****Plan****Awards:****Market****or ****Payout****Value of****Unearned****Shares,****Units or****Other****Rights****That****Have ****Not****Vested** |   |
| William                N. Plamondon, III |   |                                                                                             | 1,575,000 |                                                                                               |   | 0 |   |   | 0 |   | $ | 0.67 |   |   | 6/30/2008 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             |      |                                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| James                B. McCarthy         |   |                                                                                             | 80,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.77 |   |   | 6/01/2015 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 40,000    |                                                                                               |   | 40,000 |   |   | 0 |   |   | 0.20 |   |   | 6/01/2016 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             |      |                                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Joseph                Cappello, Ph.D.    |   |                                                                                             | 25,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 1.38 |   |   | 7/07/2008 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 50,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.75 |   |   | 11/23/2008 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 42,500    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.47 |   |   | 6/15/2009 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 10,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.88 |   |   | 9/26/2010 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 50,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.80 |   |   | 4/12/2011 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 20,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.85 |   |   | 5/29/2011 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 50,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.37 |   |   | 11/25/2012 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 1,350,000 |                                                                                               |   | 0 |   |   | 0 |   |   | 0.73 |   |   | 4/25/2013 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 24,306    |                                                                                               |   | 694 |   |   | 0 |   |   | 0.65 |   |   | 1/03/2015 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             |      |                                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |
| Franco                A. Ferrari, Ph.D.  |   |                                                                                             | 20,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 1.38 |   |   | 7/07/2008 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 50,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.75 |   |   | 11/23/2008 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 30,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.47 |   |   | 6/15/2009 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 10,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.88 |   |   | 9/26/2010 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 50,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.80 |   |   | 4/12/2011 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 20,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.85 |   |   | 5/29/2011 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 50,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.37 |   |   | 11/25/2012 |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                     |   |                                                                                             | 1,200,000 |                                                                                               |   | 0 |   |   | 0 |   |   | 0.73 |   |   | 4/25/2013 |   |   | - |   |   | - |   |   | - |   |   | - |   |
|                                     |   |                                                                                             | 24,306    |                                                                                               |   | 694 |   |   | 0 |   |   | 0.65 |   |   | 1/03/2015 |   |   |   |   |   |   |   |   |   |   |   |   |   |
|                                     |   |                                                                                             |      |                                                                                               |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |   |  |   |
| Erin                Davis                |   |                                                                                             | 75,000    |                                                                                               |   | 0 |   |   | 0 |   |   | 0.67 |   |   | 6/30/2008 |   |   | - |   |   | - |   |   | - |   |   | - |   |

----

| **Item                11.** | **Security                Ownership of Certain Beneficial Owners and Management****and****Related                Stockholder Matters** |
|-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| (i) | all                persons known by the Company to be the beneficial owner of more than                5% of                the common stock, Series D Preferred Stock (on an as converted basis),                Series F Preferred Stock (on an as converted basis), Series G Preferred                Stock (on an as converted basis), Series H Preferred Stock (on an                as                converted basis) and Series I Preferred Stock (on an as converted                basis), |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii) | all                directors and nominees for directors, |
|------|----------------------------------------------------------|

| (iii) | each                executive officer named below, and |
|-------|--------------------------------------------------------|

| (iv) | all                directors and executive officers as a group. |
|------|-----------------------------------------------------------------|

----

| Name and Address                                                                                                                                                            |   | Amount & Natureof Beneficial |                                                                           | Approximate |   |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|-------------------------------------------------|--------------------------------------------------------------------------------|-------------|--------|
| of Beneficial Owner                                                                                                                                                         |   | Ownership                                       |               | Percentage* |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| William                N. Plamondon, III(1)                                                                                                                                           |   |                                            | -0-                                                                            |        |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Richard                Adelson(1)                                                                                                                                                     |   |                                            | 66,600                                                                         | (3)         |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Allan                Farber(1)                                                                                                                                                        |   |                                            | 699,893                                                                        | (4)         |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Kerry                L. Kuhn, MD(1)                                                                                                                                                   |   |                                            | 798,947                                                                        | (5)         |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| James                B. McCarthy(1)(2)                                                                                                                                                |   |                                            | 138,947                                                                        | (6)         |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Joseph                Cappello, Ph.D.(2)                                                                                                                                              |   |                                            | 1,673,248                                                                      | (7)         |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Franco                A. Ferrari, Ph.D.(2)                                                                                                                                            |   |                                            | 1,536,359                                                                      | (8)         |   | ** |   |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Redec                & Associates, LLC c/o                Protein Polymer Technologies, Inc. 10655                Sorrento Valley Road San                Diego, California 92121 |   |                                            | 13,276,658                                                                     | (9)         |   | 11.1 | % |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Johnson                & Johnson Development Company One                Johnson & Johnson Plaza New                Brunswick, New Jersey 08933                                |   |                                            | 60,727,876                                                                     | (10)        |   | 36.4 | % |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| Matthew                Szulik c/o                Protein Polymer Technologies, Inc. 10655                Sorrento Valley Road San                Diego, California 92121              |   |                                            | 85,412,806                                                                     | (11)        |   | 44.6 | % |
|                                                                                                                                                                                  |   |                                            |                                                                                |        |   |  |   |
| All                Officers and Directors as a Group                                                                                                                                  |   |                                            | 4,913,994                                                                      | (3)-(8)     |   | 4.5 | % |

----

----

| * | Based                upon 106,207,982 shares issued and outstanding as of July 21, 2008                except                as otherwise provided in the                footnotes. |
|---|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| ** | Less                than 1%. |
|----|------------------------------|

| (1) | Director                or Director nominee. |
|-----|----------------------------------------------|

| (2) | Executive                Officer. |
|-----|-----------------------------------|

| (3) | Includes                i) 50,000 shares subject to options exercisable within 60 days and                ii)                3,400 shares owned by the stockholder’s spouse. Excludes 1,392,372 shares                of common stock held in trust for the stockholder’s mother. The                stockholder disclaims beneficial ownership of the shares owned in                trust                for his mother. |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (4) | All                shares are owned by the stockholder’s spouse. Includes 45,455 shares                issuable upon conversion of Series I Preferred Stock within 60                days. |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (5) | Includes                (i) 343,947 shares subject to options exercisable within 60 days                and (ii)                80,000 shares issuable upon conversion of Series G Preferred Stock                convertible within 60 days. |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (6) | Includes                138,947 shares subject to options exercisable within 60                days. |
|-----|------------------------------------------------------------------------------------------------------|

| (7) | Includes                1,597,500 shares subject to options exercisable within 60                days.  |
|-----|--------------------------------------------------------------------------------------------------------------|

| (8) | Includes                1,435,000 shares subject to options exercisable within 60                days. |
|-----|--------------------------------------------------------------------------------------------------------|

| (9) | Includes                (i) 554,545 shares issuable upon conversion of shares of Series I                Preferred Stock convertible within 60 days and (ii) 1,594,622 shares                subject to warrants exercisable within 60                days. |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (10) | Includes                (i) 1,868,750 shares issuable upon conversion of shares of Series                D                Preferred Stock convertible within 60 days; (ii) 55,041,665 shares                issuable upon conversion of shares of Series F Preferred Stock convertible                within 60 days; (iii) 1,078,800 shares issuable upon conversion of                shares                of Series H Preferred Stock convertible within 60 days; (iv) 1,818,181                shares issuable upon conversion of shares of Series I Preferred Stock                convertible within 60 days." |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (11) | Includes                (i) 127,272 shares issuable upon conversion of the Company’s Series I                Preferred Stock convertible within 60 days and (ii) 36,198,041 shares                subject to warrants exercisable within 60                days. |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **Item                12.** | **Certain                Relationships and Related                Transactions** |
|-----------------------------|----------------------------------------------------------------------------------|

----

**Material      Relationship with the Company**

| **Item                13.** | **Exhibits** |
|-----------------------------|--------------|

| 31.1 | Certification                of Chief Executive Officer pursuant to Securities Exchange Act Rules                13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002.                    |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 31.2 | Certification                of Principal Financial Officer pursuant to Securities Exchange Act                Rules                13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002. |
| 32.1 | Certification                of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as                adopted                pursuant to Section 906 of the Sarbanes-Oxley Act of                2002.                                |
| 32.2 | Certification                of Principal Financial Officer pursuant to 18 U.S.C. Section 1350                as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of                2002.                                       |

| **Item                14.** | **Principal                Accountant Fees and                Services** |
|-----------------------------|--------------------------------------------------------------------------|

|   | · | Audit                Fees: Aggregate fees billed for professional services rendered for                the                audit of our annual financial statements for the fiscal years ended                December 31, 2006 and December 31, 2007 and for review of our financial                statements included in our quarterly reports on Form 10-QSB for those                years were approximately $105,626 and $114,469,                respectively. |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | Audit-Related                Fees: There were no fees billed for assurance and related services                reasonably related to the performance of the audit or review of our                financial statements and not reported under “Audit Fees” above in the                fiscal years ended December 31, 2006 and December 31,                2007. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

|   | · | Tax                Fees. Aggregate fees billed for tax services were approximately $3,465                and                $6,588 in the fiscal years ended December 31, 2006 and December 31,                2007,                respectively. These fees were primarily for compliance fees for the                preparation of tax returns, assistance with tax planning strategies,                and                tax advice. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | · | All                Other Fees: There were no fees billed for services other than those                described above in the fiscal years ended December 31, 2006 and December                31, 2007. These fees were primarily for review of registration statements                and issuances of consents. |
|--------|--------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**SIGNATURES**

|                             | PROTEIN                  POLYMER TECHNOLOGIES, INC. |
|----------------------------------|-----------------------------------------------------|
|                             |                                                |   |
| August                  12, 2008 | By:                                                 | /S/                  JAMES B. MCCARTHY |
|                             |                                                | James                  B. McCarthy   |
|                             |                                                | Interim                  Chief Executive Officer  |

| Signature                                   |   | Capacity                                               |   | Date                                  |
|---------------------------------------------|--------|--------------------------------------------------------|--------|---------------------------------------|
|                                        |   |                                                   |   |                                  |
| /S/                JAMES B. MCCARTHY        |   | Interim                Chief Executive Officer         |   | August                12 , 2008  |
| James                B. McCarthy            |   | and                Interim Principal Financial Officer |   |                                  |
|                                        |   |                                                   |   |                                  |
| /S/                ALLAN FARBER             |   | Director                                               |   | August                12 , 2008       |
| Allan                Farber                 |   |                                                   |   |                                  |
|                                        |   |                                                   |   |                                  |
| /S/                KERRY L. KUHN            |   | Director                                          |   | August                12 , 2008       |
| Kerry                L. Kuhn, M.D.          |   |                                                   |   |                                  |
|                                        |   |                                                   |   |                                  |
| /S/                RICHARD ADELSON          |   | Director                                          |   | August                12 , 2008       |
| Richard                Adelson              |   |                                                   |   |                                  |
|                                        |   |                                                   |   |                                  |
| /S/                WILLIAM N. PLAMONDON III |   | Director                                          |   | August                12, 2008        |
| William                N. Plamondon III     |   |                                                   |   |                                  |

----

**EXHIBIT      INDEX**

| 31.1   | Certification                of Chief Executive Officer pursuant to Securities Exchange Act Rules                13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002.                    |
|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |                                                                                                                                                                                                                                          |
| 31.2   | Certification                of Principal Financial Officer pursuant to Securities Exchange Act                Rules                13a-14(a)/15d-14(a), as adopted pursuant to Section 302 of the                Sarbanes-Oxley Act of 2002. |
|   |                                                                                                                                                                                                                                          |
| 32.1   | Certification                of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as                adopted                pursuant to Section 906 of the Sarbanes-Oxley Act of                2002.                                |
|   |                                                                                                                                                                                                                                          |
| 32.2   | Certification                of Principal Financial Officer pursuant to 18 U.S.C. Section 1350                as adopted pursuant to Section 960 of the Sarbanes-Oxley Act of                2002.                                       |

----